Dynavax Technologies Corporation Message Board

Pg 15 hmmmm....

In the context of tax liabilities, the ten year tax holiday at the facility in Switzerland, and NOLs in the US to offset taxes. "I suppose that depends on our sales level, certainly if we are wildly successful we'll be glad to pay taxes but again we are working through that process. As you mentioned, we do have a significant NOL carry forward that we'll be able to utilize going forward so there's other things that limit that including change in ownership"

Fly on the wall
Arena Pharma has positive read through from Eisai forecast, says Piper Jaffray

After Arena Pharmaceutical's partner, Eisai, predicted that sales of Arena's Belviq anti-obesity drug could reach $200M in its fiscal year ended in March 2014, Piper thinks its estimate of $22M of Belviq sales in 2013 looks conservative. The firm keeps an Overweight rating on Arena

competitor. Well done especially for a small startup Biotech.

VVUS is dead in the water

Huge write off for expired product

on the workaround sure points to an agreement soon.

ARS Tech (trade publication) believes so.

by Jacqui Cheng - Apr 26 2013, 10:29am CDT

iOS & iDevices
Patents
5

Apple has walked back its decision to make changes to how iOS devices handle VPN following a $368.2 million patent verdict in favor of VirnetX. Apple originally posted a support document to its website earlier this month detailing how the settings would change when iOS users connect to VPN networks, but it updated the document this week to say the changes are no longer happening.

When Apple first posted the document, it specifically pointed to the lawsuit by patent firm VirnetX as the reason for the behavior change on iOS's VPN On Demand feature. The change was going to be relatively minor—devices with VPN On Demand configured to "always" would instead behave as if they were set up to only establish a connection as needed.

As noted by MacRumors, some users pointed out that this option doesn't always perform as expected. Luckily for them, it looks like the "always" option will remain as part of VPN On Demand—Apple's updated document hints that it came to an agreement with VirnetX and was able to keep things the same without issuing any kind of software update.

"Apple no longer plans to change the behavior of the VPN On Demand feature of iOS 6.1 for devices that have already been shipped. The 'Always' option will continue to work as it currently does on these devices," wrote Apple.

We're going back up!!

I predict an investigation very soon.

LOCATION for the meeting. Why not simply say the Annual Meeting will be on July 9th??

From the SEC Filing on 3/28/13: "the Company’s annual general meeting of shareholders in 2013, which is CURRENTLY SCHEDULED for July 9, 2013.

From the SEC Filing on 3/25/13: NOTICE IS HEREBY GIVEN that the Annual General Meeting of Shareholders of Amarin Corporation plc, a company registered in England and Wales (the “ Company ”), will be held at The Shelbourne Hotel, 27 St. Stephen’s Green, Dublin 2, Ireland on July 9, 2013 at 8:00 a.m. local time for the purpose of considering and, if thought fit, passing the following resolutions

this guy is on target

Diabetes Drugs May Cause Damage to Pancreas, Study Finds

By Albertina Torsoli - Mar 22, 2013 3:20 PM CT.

People taking diabetes drugs such as Merck & Co. (MRK)’s Januvia were affected by pancreatic cell growth and damage that may turn cancerous, a small study found.

The study, led by Alexandra Butler and Peter Butler of the University of California, Los Angeles, provides evidence of increased pre-cancerous changes in diabetic patients using so- called incretin mimetics, Public Citizen, a Washington-based public advocacy group, said in a statement today after the research was published.

Merck & Co. diabetes treatment Januvia is arranged for a photograph. People taking diabetes drugs such as Januvia were affected by pancreatic cell growth and damage that may turn cancerous, a small study found. Photographer: JB Reed/ Bloomberg
.
The U.S. Food and Drug Administration said this month it was reviewing unpublished findings by a group of academic researchers suggesting pre-cancerous cellular changes may be associated with Type 2 diabetes treatments known as incretin mimetics, which also include Bristol-Myers Squibb Co. (BMY)’s Byetta and Novo Nordisk A/S’s (NOVOB) Victoza.

“These findings are in accord with the rapidly increasing number of reports to the U.S Food and Drug Administration of pancreatic cancer in patients using these drugs compared with diabetics using other drugs,” Public Citizen said.

Doctors have been concerned that this category of diabetes treatments may damage the pancreas since the FDA said in 2007 it received a high number of reports of pancreatitis in patients taking Byetta. The agency issued a similar alert for Januvia in 2009. An analysis of insurance records published last month in the journal JAMA Internal Medicine showed such drugs may double a user’s risk of pancreatitis. That hasn’t stopped these medicines from becoming multibillion-

NICE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

This article was sent to 118,242 people who get email alerts on AAPL.